Insmed Incorporated (NASDAQ:INSM) Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. decreased its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 23.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,456 shares of the biopharmaceutical company's stock after selling 27,195 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.06% of Insmed worth $6,384,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. JCIC Asset Management Inc. purchased a new stake in Insmed during the third quarter valued at about $133,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Insmed by 18.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 390,134 shares of the biopharmaceutical company's stock worth $28,480,000 after purchasing an additional 62,061 shares during the period. Blue Trust Inc. increased its position in Insmed by 2,348.8% during the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company's stock worth $131,000 after purchasing an additional 1,879 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in Insmed in the third quarter valued at approximately $30,000. Finally, Creative Planning lifted its position in Insmed by 31.2% during the third quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company's stock valued at $3,279,000 after buying an additional 10,668 shares in the last quarter.

Insmed Stock Performance

Insmed stock traded down $0.23 during mid-day trading on Thursday, reaching $71.71. The company's stock had a trading volume of 805,025 shares, compared to its average volume of 2,303,742. The firm has a market cap of $10.66 billion, a price-to-earnings ratio of -13.76 and a beta of 1.11. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53. The business has a 50 day moving average price of $73.98 and a 200-day moving average price of $59.42. The company has a current ratio of 2.71, a quick ratio of 2.53 and a debt-to-equity ratio of 25.05.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analyst estimates of $87.95 million. During the same period in the previous year, the company posted ($1.78) earnings per share. The firm's revenue was up 17.0% on a year-over-year basis. Sell-side analysts predict that Insmed Incorporated will post -5.41 EPS for the current fiscal year.

Insider Transactions at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of the company's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now owns 100,100 shares in the company, valued at approximately $7,157,150. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Martina M.D. Flammer sold 13,436 shares of the business's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now owns 106,134 shares of the company's stock, valued at approximately $7,951,559.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

INSM has been the subject of several recent research reports. Bank of America increased their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research note on Monday, September 9th. Morgan Stanley increased their target price on Insmed from $60.00 to $85.00 and gave the company an "overweight" rating in a research note on Friday, July 12th. TD Cowen upped their price target on Insmed from $75.00 to $98.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Finally, The Goldman Sachs Group increased their price objective on shares of Insmed from $74.00 to $102.00 and gave the company a "buy" rating in a research report on Wednesday, July 10th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $82.73.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.